Journal
BIOLOGICAL & PHARMACEUTICAL BULLETIN
Volume 27, Issue 10, Pages 1642-1648Publisher
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/bpb.27.1642
Keywords
aging; Japanese patient; metoprolol; nonlinear mixed effects model (NONMEM); pharmacokinetics; whole blood concentration
Categories
Ask authors/readers for more resources
This study was performed to estimate the mean pharmacokinetic parameters of routinely administered metoprolol in middle-aged and elderly Japanese patients. Whole blood concentration data (65 samples) at steady-state following repetitive administration to 34 patients were analyzed using a nonlinear mixed effects model. A one-compartment model was parameterized in terms of oral clearance (CLIF) and apparent volume of distribution (V/T). We evaluated the effect of polymorphic alleles (CYP2D6*2, CYP2D6*10, CYP209*2 and CYP209*3), age, gender, and heart failure on the pharmacokinetic parameters of metoprolol. The CLIF value in patients homozygous for the CYP2D6*10 allele was 64% lower than that in patients with a CYP2D6*1/*1 or *1/*2 genotype. The CLIF value in older (>70 years old) patients was 26% lower than that in younger (less than or equal to70 years old) patients. In addition, the V/F value in patients homozygous for the CYP2D6*10 allele was 25% lower than that in patients with the CYP2D6*1/*1 or *1/*2 genotype. On the other hand, the CYP2C19 genotype, gender, and heart failure showed no significant effects on the pharmacokinetics of metoprolol. The results suggest that the pharmacokinetic variability of metoprolol in Japanese extensive metabolizers of CYP2D6 is very large, probably because CYP2D6*10 is responsible not only for the decreased systemic clearance (CL) but also for the increased bioavailability (F) of the drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available